Papillary type I vs type II renal cell carcinoma
Papillary renal cell carcinoma (pRCC) is the second most common [...]
Artificial intelligence for kidney cancer diagnosis
In a presentation at the 19th Meeting of the European Association [...]
ESMO 2021: Cancer and COVID-19: Outcomes and risk factors
This year there was some very important data presented at [...]
Association of immune-related adverse events and outcomes in kidney cancer
Previous studies have shown that cancer patients who experience immune-related [...]
Patterns of metastases for clear cell, papillary and chromophobe RCC associated with survival
A recent study published in JAMA Network Open looked at [...]
Most coronavirus-positive cancer patients are asymptomatic
Most studies have shown that many cancer patients are at [...]
Pazopanib for poor risk kidney cancer patients
Pazopanib is used for first-line metastatic RCC treatment, but the [...]
Partial nephrectomy for patients with rare Xp11.2 translocation kidney cancer
XP11.2 translation renal cell carcinoma (RCC) is a very rare [...]
COVID-19 outcomes with anticancer treatments
There is a lot of ongoing research to understand the [...]
Impact of delay in surgery or time to surgery on kidney cancer outcomes
A recent study published in the Journal of Urology this [...]
